Compare AEVA & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEVA | EVO |
|---|---|---|
| Founded | 2019 | 1993 |
| Country | United States | Germany |
| Employees | 239 | 4553 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 934.1M |
| IPO Year | N/A | N/A |
| Metric | AEVA | EVO |
|---|---|---|
| Price | $19.80 | $2.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $26.50 | $7.00 |
| AVG Volume (30 Days) | ★ 2.0M | 94.1K |
| Earning Date | 05-06-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $85.37 | $1.37 |
| Revenue Next Year | $132.72 | $10.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.83 | $2.31 |
| 52 Week High | $38.79 | $4.80 |
| Indicator | AEVA | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 63.18 | 36.41 |
| Support Level | $12.66 | $2.32 |
| Resistance Level | $21.64 | $3.78 |
| Average True Range (ATR) | 2.04 | 0.09 |
| MACD | 0.55 | -0.06 |
| Stochastic Oscillator | 77.04 | 7.19 |
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The 4D LiDAR sensors are designed to detect both velocity and position, supporting perception and decision-making in automated systems. The company operates in North America, EMEA, and Asia. The company's revenue consists of sales of perception solutions or sensing systems and non-recurring engineering services. Geographically, it derives the majority of its revenue from North America.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.